These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28981251)

  • 1. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen.
    de Jesus Cortez F; Nguyen P; Truillet C; Tian B; Kuchenbecker KM; Evans MJ; Webb P; Jacobson MP; Fletterick RJ; England PM
    ACS Chem Biol; 2017 Dec; 12(12):2934-2939. PubMed ID: 28981251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
    Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
    Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
    Liu H; An X; Li S; Wang Y; Li J; Liu H
    Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circumventing anti-androgen resistance by molecular design.
    McGinley PL; Koh JT
    J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogens act as selective androgen receptor modulators at the proteome level in prostate cancer cells.
    Brooke GN; Gamble SC; Hough MA; Begum S; Dart DA; Odontiadis M; Powell SM; Fioretti FM; Bryan RA; Waxman J; Wait R; Bevan CL
    Mol Cell Proteomics; 2015 May; 14(5):1201-16. PubMed ID: 25693800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
    Liu H; Han R; Li J; Liu H; Zheng L
    J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
    Kandil SB; McGuigan C; Westwell AD
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
    Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
    Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
    Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
    Bassetto M; Ferla S; Pertusati F; Kandil S; Westwell AD; Brancale A; McGuigan C
    Eur J Med Chem; 2016 Aug; 118():230-43. PubMed ID: 27131065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
    Colabufo NA; Pagliarulo V; Berardi F; Contino M; Inglese C; Niso M; Ancona P; Albo G; Pagliarulo A; Perrone R
    Eur J Pharmacol; 2008 Dec; 601(1-3):38-42. PubMed ID: 18992739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
    Liu B; Geng G; Lin R; Ren C; Wu JH
    Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging.
    Parent EE; Dence CS; Jenks C; Sharp TL; Welch MJ; Katzenellenbogen JA
    J Med Chem; 2007 Mar; 50(5):1028-40. PubMed ID: 17328524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of urolithins on the response of prostate cancer cells to non-steroidal antiandrogen bicalutamide.
    Stanisławska IJ; Piwowarski JP; Granica S; Kiss AK
    Phytomedicine; 2018 Jul; 46():176-183. PubMed ID: 30097116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for antagonism and resistance of bicalutamide in prostate cancer.
    Bohl CE; Gao W; Miller DD; Bell CE; Dalton JT
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6201-6. PubMed ID: 15833816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.